OTC : BIOAF

Bioasis Technologies Inc.

$0.0001 USD

$0 (0.0%)

Volume
72.94K
Average Volume
68.08K
Market Capitalization
$7.94K
P/E Ratio
-0.12
Dividend Yield
0.00%
Price Target
Year High
$0.00
Year Low
$0.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.70
Company Overview

OTC

Deborah Ann Rathjen

Biotechnology

Healthcare

BIOAF

4

US

USD

https://www.bioasis.us

203 533 7082

09064N103

N/A

Liquidity Metrics

-0.99

0.70

0.70

0.58

0.00

Sales & Valuation

$37725

10.53

-0.19

-0.11

-0.05

Profitability

-$0.041

-$2.96M

-7846.50%

-7846.50%

392.02%

-130.64%

P/E Metrics

-0.12

-0.01

-0.01

Analyst Price Target & Rating

N/A

0/5

0 Analysts

%

Poll Results

About Bioasis Technologies Inc. (OTC:BIOAF) Stock

Bioasis Technologies Inc. is a developing biopharmaceutical enterprise dedicated to the discovery and advancement of treatments and diagnostic tools for various neurological conditions. Central to its strategy is the proprietary xB3 platform, an innovative technology designed to overcome the blood-brain barrier (BBB) and effectively deliver therapeutic agents to the central nervous system (CNS). This platform targets a range of CNS disorders, including brain cancers, metabolic illnesses, and neurodegenerative diseases. The company's internal development pipeline includes several promising candidates: xB3-001, aimed at treating brain metastases; xB3-002, focused on glioblastoma; and xB3-007, targeting neurodegenerative diseases. These programs strive to offer both symptomatic relief and dis ... ease-modifying interventions. Bioasis also engages in strategic alliances to expand its research and development capabilities. It collaborates with Aposense Limited on the delivery of siRNA therapeutics for CNS disorders, and with Oxyrane UK Ltd. to integrate xB3 with Oxyrane's OxyCAT platform, enhancing enzyme replacement therapy delivery to the brain. Furthermore, a partnership with Janssen Biotech, Inc. focuses on the research, development, and commercialization of novel xB3-based products. A separate collaboration and licensing agreement with Neuramedy Co Ltd. involves the joint development and commercialization of an xB3-optimized version of their antibody, Tomaralimab. Established in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.

Financial Analysis: Prelude Therapeutics (NASDAQ:PRLD) versus Bioasis Technologies (OTCMKTS:BIOAF)

2026-04-27 02:24:43

Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Bioasis Technologies (OTCMKTS:BIOAF - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk. Institutional and Insider Ownership 79.7% of Prelude Therapeutics

Frequently Asked Questions

What is the current Bioasis Technologies Inc. (BIOAF) stock price?

Bioasis Technologies Inc.(OTC:BIOAF) stock price is $0.0001 in the last trading session. During the trading session, BIOAF stock reached the peak price of $0.0002 while $0.0001 was the lowest point it dropped to. The percentage change in BIOAF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BIOAF stock was $0.

BIOAF's industry and sector of operation?

The OTC listed BIOAF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BIOAF?

Aaron Elton | Director of Marketing
Mei Mei Tian | Vice President & Head of External Research
David Jenkins | Chief Financial Officer
Graeme Dick | Director of Investor Relations
Deborah Ann Rathjen FTSE | Chief Executive Officer & President

How many employees does BIOAF have?

Number of BIOAF employees currently stands at 4. BIOAF operates from 157 Church Street, New Haven, CT 06510, US.

Link for BIOAF official website?

Official Website of BIOAF is: https://www.bioasis.us

How do I contact BIOAF?

BIOAF could be contacted at phone #203 533 7082 and can also be accessed through its website. BIOAF operates from 157 Church Street, New Haven, CT 06510, US.

How many shares of BIOAF are traded daily?

The average number of BIOAF shares traded daily for last 3 months was 68.08K.

What is the market cap of BIOAF currently?

The market value of BIOAF currently stands at $7.94K with its latest stock price at $0.0001